Delivery Order SPE2DB24D3015-SPE2DB25FFYEL

Award Date 2/24/25
Potential Completion Date 3/17/25
Potential Value $7.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a global pharmaceutical distribution company. The $3,518.40 order is for the supply of 120 tablets of the pharmaceutical product NUBEQA 300 MG. The delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of up to...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of NUBEQA 300 MG TABLET 120S, a specialty pharmaceutical product. The total ceiling value of the contract is $7,641.98, with a completion date of January 29, 2025. The contract is a Firm Fixed Price (FFP) arrangement and is not designated as a set-aside award. AmerisourceBergen holds a significant Indefinite Delivery...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of 120 tablets of the pharmaceutical product NUBEQA 300 MG. The potential value of this delivery order is $14,073.60, with a completion date of March 21, 2024. Amerisourcebergen Drug Corp is the prime contractor and this contract does not have a set-aside designation. The...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,641.98, is for the delivery of 120 tablets of NUBEQA 300 mg, a medication used in the treatment of prostate cancer. The award has an ultimate completion date of February 18, 2025. This contract is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,641.98, is for the supply of NUBEQA 300 MG TABLET 120S, a prescription pharmaceutical product. The contract is a firm fixed-price delivery order with a completion date of March 19, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $10,920.00 and a completion date of February 24, 2025. The contract is for the delivery of NUBEQA 300 MG TABLET 120S, a pharmaceutical product. The contract is a firm fixed-price delivery order and does not have a set-aside designation, indicating open competition....
This federal contract award, valued at $4,683.97, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 120 tablets of the drug NUBEQA 300 MG, and has a completion date of November 12, 2024. The contract is a Delivery Order, with a Firm Fixed Price pricing type. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with...
This federal contract award, valued at $7,641.98, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of February 3, 2025. The contract is for the supply of the drug NUBEQA 300 MG TABLET 120S. This contract is not associated with a set-aside program. Amerisourcebergen Drug Corp holds a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,641.98, is for the delivery of NUBEQA 300 MG TABLET 120S, a pharmaceutical product. The contract is a delivery order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $7,036.80 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,042,325 units of the pharmaceutical product NUBEQA 300 MG TABLET 120S. This delivery order falls under a larger indefinite delivery contract (IDC) worth up to $999,999,999.00 awarded to Amerisourcebergen Drug Corp by DLA to supply a comprehensive range of medications and medical supplies to support...
  • SPE2DB24D3015
    Indefinite Delivery Contract
  • SPE2DB24D3015-SPE2DB25FFYEL
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 120 tablets of the medication NUBEQA 300 MG. The contract has a ceiling value of $7,641.98 and a completion date of March 17, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 6/1/25, 3:04 AM